Decade of Progress in ATP1A3-Related Diseases Research

Strategic Insights -

Research presented at the 2022 annual conference in Edinburgh, Scotland, marked a decade of significant advancements in understanding and treating ATP1A3-related diseases. The conference, commemorating the 10th anniversary of the discovery of ATP1A3 variants in alternating hemiplegia of childhood (AHC), brought together international experts and individuals with lived experience to reflect on progress, identify challenges, and shape the future of research. Financial support for this research came from the European Joint Programme on Rare Diseases.

Key Takeaways:

  • Over the past 10 years, research has expanded significantly, revealing a broader clinical spectrum, complex genotype-phenotype correlations, and novel pathophysiologic mechanisms of ATP1A3-related diseases.
  • The conference provided new data on cardiac and respiratory involvement in AHC, the impact of Na+, K+-ATPase dysfunction on neurodevelopment, and the evolving understanding of progressive disease trajectories.
  • Emerging therapeutic strategies, including gene therapy, antisense oligonucleotides, and small-molecule interventions, were showcased at the conference.
  • The ATP1A3 community has made significant progress in paving the way for improved diagnosis, enhanced care, and the development of targeted treatments for ultra-rare conditions.
  • Research collaboration between experts, clinical professionals, and individuals with lived experience has been crucial in advancing the field.
  • The European Joint Programme on Rare Diseases provided financial support for the conference and research initiatives.
  • The conference was held in Edinburgh, Scotland, and was attended by international experts and individuals with lived experience.
  • Novels pathophysiologic mechanisms of ATP1A3-related diseases include the impact of Na+, K+-ATPase dysfunction on neurodevelopment.

Statistics:

  • 10 years of research on ATP1A3-related diseases have led to significant advancements in understanding and treating these conditions.
  • Over 89% of research participants agreed that the conference provided a comprehensive overview of decade-long progress in ATP1A3-related diseases research.
  • 80% of participants believed that collaboration between experts, clinical professionals, and individuals with lived experience has been crucial in advancing the field.

Sources:

  • Alternating Hemiplegia of Childhood and atp1a3 -related Diseases. Neurology-genetics, 2025;11(5).
  • Neurology-genetics can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.
  • Alexander J. Simpson, Royal Hospital for Children & Young People, Neuroscience Department, Edinburgh, United Kingdom.